Thanks to a reduction of imported PPE, 36% of hospital respondents expect large-scale PPE shortages, while 54% have imposed PPE conservation protocols.
If the current demand for N95 masks, fueled by COVID-19 concerns, continues at its present rate, it would mean that at least 56 million of the masks would be sold in 2020, a 3-fold increase in demand when compared with a typical year.
That’s just one of the findings from a survey by the healthcare consulting company Premier, which adds to the much-noted observation that there is not enough personal protective equipment (PPE) on hand to respond to the COVID-19 challenge. As the World Health Organization noted this week, this is a global problem and the United States finds itself particularly vulnerable. About 80% of all PPE manufactured globally comes from Asia, but large producers like China, Taiwan, Thailand, India, and South Korea have stopped exporting because they need the PPE to deal with COVID-19 outbreaks in their own countries. That situation is expected to continue at least through April, according to Premier.
Eighty-six percent of US hospitals and health systems are concerned about their supply of PPE and face masks, according to the Premier survey. In January and February, the demand for N95s surged 400% and 585%, respectively, in the United States.
Michael J. Alkire, Premier’s president, said in a press release that the company provided the survey to the US Centers for Disease Control and Prevention and the US Food and Drug Administration to help the agencies plan their response to COVID-19. “Because this situation is rapidly evolving, we encourage all hospitals and health systems to initiate conservation protocols to protect stock on hand and refrain from panic-buying that can further strain the supply chain,” Alkire said.
Thanks to a reduction of imported PPE, 36% of respondents expect large-scale PPE shortages, while 54% have imposed PPE conservation protocols to help stretch the supplies that they have on hand. Forty-six percent of respondents are worried about how long current supplies will last.
David A. Hargraves, Premier’s senior vice president of supply chain services, said that “supply is unquestionably strained and health systems are going to extraordinary lengths to provide essential healthcare for their communities. Our data shows Premier members have at least two weeks of supply on hand, but that’s only if we assume current utilization rates. That number will quickly balloon if we have a domestic outbreak of coronavirus, as the Department of Health and Human Services says as many as 300 million N95 masks will be required for healthcare workers.”
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
COVID-19 Realities: Beyond a Respiratory Virus, Addressing Optimism in Pandemic Management
February 28th 2024A recent commentary by Dr. Amesh Adalja in MedPage Today challenges the perception of COVID-19 as solely a respiratory virus, highlighting its broader impact on the body. This analysis questions the notion that COVID-19 should be managed like common respiratory infections, urging a closer look at vaccine effectiveness, the rise of long COVID, and the need for enhanced measures to curb the virus's spread. Let's explore the complexities of COVID-19 management and the pressing realities faced by the US and the world.